GHRP-6: Molecular Structure

Molecular Characterization#

GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) is a synthetic hexapeptide with the molecular formula C46H56N12O6 and a molecular weight of 873.01 Da. The peptide incorporates two D-amino acids (D-Trp at position 2 and D-Phe at position 5), which confer resistance to enzymatic degradation and establish the specific three-dimensional conformation required for GHS-R1a receptor activation. The C-terminus is amidated, further enhancing stability and receptor affinity.

Structural Features#

Amino Acid Sequence#

The GHRP-6 sequence was developed through systematic structure-activity relationship studies starting from the enkephalin-derived peptide met-enkephalin (Tyr-Gly-Gly-Phe-Met). Researchers discovered that modifications to this opioid peptide could redirect its activity from opioid receptors to growth hormone release:

Conformational Properties#

Solution NMR studies of GHRP-6 have shown that the peptide adopts a partially ordered conformation in aqueous solution, with the two D-amino acids creating a characteristic beta-turn-like structure. The hydrophobic aromatic residues (D-Trp, Trp, D-Phe) form a cluster that is essential for receptor engagement. This amphipathic character — with hydrophobic aromatics on one face and charged/polar residues on the other — allows GHRP-6 to interact effectively with the transmembrane binding pocket of GHS-R1a.

D-Amino Acid Importance#

The incorporation of D-amino acids at positions 2 and 5 serves dual purposes:

1. Metabolic stability: D-amino acids are not recognized by most endogenous proteases, extending the peptide's half-life compared to all-L analogs
2. Conformational constraint: The D-configuration reverses the local backbone geometry, positioning the aromatic side chains for optimal receptor interaction

Substitution of D-Trp2 with L-Trp completely abolishes GH-releasing activity, confirming the critical importance of stereochemistry at this position.

Receptor Binding#

GHRP-6 binds to the GHS-R1a receptor, a G protein-coupled receptor (GPCR) with seven transmembrane domains. Key binding features include:

• Binding affinity: EC50 for GH release approximately 1-10 nM in pituitary cell assays
• Receptor selectivity: GHS-R1a is the primary target, though GHRP-6 also shows weak activity at other receptors
• Signaling cascade: Gq/11-mediated phospholipase C activation, IP3 generation, intracellular calcium release, and protein kinase C activation
• Constitutive activity: GHS-R1a has significant constitutive (ligand-independent) activity, and GHRP-6 functions as a full agonist, further stimulating signaling above basal levels

Pharmacokinetics#

Absorption and Distribution#

GHRP-6 is rapidly absorbed following subcutaneous injection, with peak plasma concentrations achieved within 15-30 minutes. The peptide distributes readily to the pituitary and hypothalamus, where it exerts its GH-releasing effects. Bioavailability via subcutaneous injection is estimated at 60-70%.

Intranasal administration has also been investigated, with bioavailability of approximately 10-20% relative to intravenous dosing. This route achieves adequate GH-releasing activity but with greater variability.

Metabolism and Elimination#

As a small peptide, GHRP-6 is subject to peptidase-mediated degradation in plasma and tissues. The D-amino acids at positions 2 and 5 provide partial protection, resulting in a plasma half-life of approximately 15-30 minutes. Elimination occurs primarily through renal clearance of peptide fragments and amino acid metabolites.

Pharmacodynamic Profile#

The GH response to GHRP-6 follows a characteristic pattern:

• Onset: GH levels begin rising within 5-10 minutes of administration
• Peak: Maximum GH concentrations occur at 15-30 minutes
• Duration: GH levels return to baseline within 2-3 hours
• Magnitude: Peak GH levels of 20-80 ng/mL depending on dose and individual response

Structure-Activity Relationships#

The GHRP-6 scaffold has been extensively modified to understand which structural features are essential for activity:

• Position 1: Can be replaced by D-amino acids or other basic residues with retention of activity; deletion reduces but does not eliminate activity
• Position 2: D-Trp is optimal; replacement with other D-amino acids reduces activity; L-Trp is inactive
• Position 3: Tolerates various small amino acids; Ala provides good activity and synthetic simplicity
• Position 4: L-Trp is preferred; aromatic character is essential
• Position 5: D-Phe is optimal; aromatic D-amino acids maintain activity; non-aromatic residues lose activity
• Position 6: Lys contributes to solubility; C-terminal amidation is important for full activity

These SAR findings led to the development of more potent and selective GHS peptides (GHRP-2, hexarelin, ipamorelin) and ultimately to the non-peptide GHS agonist MK-0677 (ibutamoren), which has oral bioavailability.

Related Reading#

• GHRP-6 overview and research guide
• Peptides similar to GHRP-6
• GHRP-6 research evidence